Conclusion and Results
In 2023, one and a half weeks after her final dose of intravenous
ketamine 1200 milligrams, her pain remained 4 out of 10. The patient
consumed 2 grams, 5.5 grams, and then 3.5 grams of psilocybe cubensis
mushrooms. The second dose was three days after the first, and the third
was two days later. Alongside dosing sessions, the patient partook in
adjunctive neuromechanics, neurovisual modulation, and tactile
reprocessing programming. Leading up to the psilocybin dosing, she had
tried these adjunctive techniques alone without concurrent psilocybin
use, but did not achieve significant relief.
At one month follow-up, the pain decreased to 0 to 1 out of 10 as
recorded by the Brief Pain Inventory (BPI). She also endorsed a decrease
in mood symptoms at follow-up, supported by Montgomery-Asberg Depression
Rating Scale (MADRS), Hamilton Depression Rating Scale (HAM-D), and
Clinician-Administered PTSD Scale (CAPS) scores, as reflected in Table
1.
Her CRPS pain remained at 0 to 1 out of 10 without ketamine for 9
months. The frequency of her falls decreased by 75%, with only two
falls in the 9-month period since starting psilocybin, a significant
improvement from before. Additionally, the frequency, intensity, and
duration of glossodynia attacks have reduced by 75% each. She reports
that the attack intensity no longer rises above 2 out of 10. No
long-term adverse events after psilocybin were noted.